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Abstract
High-density lipoproteins (HDL) have many biological functions, including reducing endothelial
activation and adhesion molecule expression. We recently reported that HDL transport and deliver
functional microRNAs (miRNA). Here we show that HDL suppresses expression of intercellular
adhesion molecule 1 (ICAM-1) through the transfer of miR-223 to endothelial cells. After
incubation of endothelial cells with HDL, mature miR-223 levels are significantly increased in
endothelial cells and decreased on HDL. However, miR-223 is not transcribed in endothelial cells
and is not increased in cells treated with HDL from miR-223−/− mice. HDL inhibit ICAM-1
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protein levels, but not in cells pretreated with miR-223 inhibitors. ICAM-1 is a direct target of
HDL-transferred miR-223 and this is the first example of an extracellular miRNA regulating gene
expression in cells where it is not transcribed. Collectively, we demonstrate that HDL’s anti-
inflammatory properties are conferred, in part, through HDL-miR-223 delivery and translational
repression of ICAM-1 in endothelial cells.
Numerous population studies have established that plasma high-density lipoprotein (HDL)
cholesterol levels inversely correlate with cardiovascular risk1–4. The most extensively
studied cardio-protective function of HDL particles relate to their participation in the reverse
cholesterol transport pathway5. Studies from this and other laboratories have shown that
HDL also repress inflammatory gene expression in cytokine-activated endothelial cells and
other cell types6–9. Nevertheless, the underlying mechanisms conferring their cardio-
protective effects are poorly understood largely because HDL are heterogeneous and consist
of several structurally and functionally distinct subpopulations of particles3,10–13.
We have recently reported that HDL also transport specific microRNAs (miRNAs)14,15.
miRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression
through translational inhibition and mRNA destability16. They have proven to be powerful
regulators of many biological processes, including cellular growth, metabolism, physiology
and response to stress17,18. They are also stably found in both cells and extracellular
compartments, such as plasma, and regulate gene expression15,19. Circulating miRNAs are
potential novel class of biomarkers for cardiovascular disease and have the capacity to act as
bioactive signalling molecules17,20. Altered extracellular miRNA profiles have been
observed in inflammation, cardiovascular diseases, atherosclerosis, diabetes, obesity and
ageing19,21.
miRNAs are transcribed as primary transcripts (pri-miRNA) and further processed into
precursor (pre-miRNA) hairpins in the nucleus22. Upon nuclear export, miRNAs are cleaved
to their mature forms22. Recently, it has been shown that mature miRNAs are likely
involved in intercellular communication, a process by which miRNAs are transferred
between cells by lipid-based carriers, including exosomes, microvesicles and lipoproteins.
As such, mature miRNAs are able to regulate gene expression in cells in a novel form of
endocrine-like cell-to-cell communication14,15,23–28. miR-223 is a miRNA that is of
particular interest in cardiovascular disease as its levels are significantly increased in HDL
from humans and mice with hypercholesterolaemia14. Moreover, miR-223 is one of the most
abundant miRNAs in monocytes and macrophages and a key regulator of inflammation29.
miR-223-null (miR-223−/−) mice have a significantly increased number of circulating
neutrophils and enhanced systemic inflammation following a lipopolysaccharide
challenge29.
In this study, we demonstrate that the anti-inflammatory properties of HDL are conferred, in
part, by the transfer of miR-223 to recipient endothelial cells where it suppresses adhesion
molecule expression. Within this study, we extensively characterized the gene (mRNA) and
miRNA signatures of human coronary artery endothelial cells (HCAEC) following
incubation with HDL, which transport miRNAs including miR-223 or the individual
constituents of HDL. Studies were also carried out with reconstituted HDL consisting of 1-
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palmitoyl-2-linoleoyl phosphatidylcholine (PLPC) and apoA-I (rHDL), lipid-free
apolipoprotein A-I (apoA-I) and PLPC small unilamellar vesicles (SUV). Results indicate
that native HDL particles and their individual lipid and apolipoprotein constituents
differentially alter the expression of numerous genes and the levels of several miRNAs in
HCAEC. Moreover, we found that HDL transfer of miR-223 to endothelial cells, where
miR-223 is not transcribed or processed, contributes to the mechanisms by which HDL
inhibit inflammation in HCAEC.
Results
HDL constituents control gene expression in HCAEC
HDL have previously been reported to alter gene expression in multiple cell types; however,
it is unclear whether it is the lipid or apolipoprotein constituents, with apoA-I being the most
abundant HDL apolipoprotein, that contribute to this gene regulation5,12,30. To characterize
the endothelial cell response to intact native HDL particles, as well as to their lipid and
apolipoprotein constituents, non-activated HCAEC were incubated for 16 h with native
human HDL, rHDL, lipid-free apoA-I or SUV. Results from SDS–PAGE analyses indicate
that the apoA-I preparations were > 95% pure (Supplementary Fig. 1A). The rHDL
preparations had a final PLPC/apoA-I molar ratio of 80:1 and consisted of three
subpopulations of particles with 8.7, 9.8 and 11.8 nm diameters (Supplementary Fig. 1B).
The plasma concentration of human HDL constituents is presented in Supplementary Table
1. These preparations consisted of multiple subpopulations of particles ranging from ~7.0 to
10.0 nm in diameter (Supplementary Fig. 1C).
Changes in gene (mRNA) expression were analysed by whole-genome gene arrays.
Significant and differential gene changes were observed in HCAEC treated with SUV (124
in total; 31 up; 93 down), lipid-free apoA-I (1 down), rHDL (182 in total; 113 up; 69 down)
and native human HDL (120 in total; 19 up; 101 down) (Benjamini–Hochberg-corrected P <
0.05; ≥ 1.5-fold; Fig. 1a–d red circles, Supplementary Data 1). Each HDL constituent,
except lipid-free apoA-I, significantly altered the expression of a diverse set of genes, many
of which are associated with inflammation (Supplementary Data 1). Strikingly, a group of
shared genes were similarly altered (24 downregulated, green circle; 1 upregulated, red
circle) by SUV, rHDL and native HDL (Fig. 1e). As the common feature of SUV, rHDL and
native HDL is their ability to accept unesterified cholesterol from cell membranes, these
genes are likely altered in response to cholesterol efflux, and therefore, were classified as the
‘cholesterol efflux responsive gene set’ (Fig. 1e green and red circles, Supplementary Table
2). Ingenuity Pathway Analyses identified 19 significantly downregulated pathways and 1
upregulated pathway associated with the cholesterol efflux responsive gene set, with the
interferon signalling pathway being the most significantly altered pathway (Supplementary
Table 3). Most importantly, each HDL constituent significantly altered distinct canonical
pathways: native HDL treatment altered 26 pathways (Supplementary Table 4), rHDL
treatment altered 19 pathways (Supplementary Table 5) and SUV treatment altered 25
pathways (Supplementary Table 6). The most altered pathway by native HDL was the
clathrin-mediated endocytosis signalling pathway (Supplementary Table 4). Other signalling
pathways that were altered by incubation with HDL included the inflammatory nuclear
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factor-kappaB (NF-κB) signalling pathway (Supplementary Table 4). Within the NF-κB
pathway, interleukin 33 (IL33, −1.75-fold, Benjamini–Hochberg-corrected P < 0.05),
phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide
(PIK3C2B, −1.5-fold, Benjamini–Hochberg corrected P < 0.01) and tumor necrosis factor,
alpha-induced protein 3 (TNFAIP3, −1.88-fold, Benjamini–Hochberg corrected P < 0.01)
were all significantly decreased at the mRNA level (Supplementary Table 7).
Native HDL gene regulation is distinct from its components
To determine which genes in HCAEC are regulated specifically by native HDL, the genes
that were altered only by apoA-I, rHDL and SUV treatments were excluded from the
analysis. Using this approach, we identified 49 unique genes that were altered in HCAEC by
native HDL treatments alone (Supplementary Table 7). It is well established that increased
vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1
(ICAM-1) expression in response to endothelial activation is mediated through the
transcription factor NF-κB31,32. We have previously reported that HDL inhibit cytokine-
induced ICAM-1 and VCAM-1 expression in activated endothelial cells through the NF-κB
pathway7,33,34. To determine whether HDL suppress inflammatory gene expression as a
homoeostatic mechanism, whole-genome gene arrays were used with RNA from non-
activated HCAEC. We found that ICAM-1 mRNA levels were significantly decreased by
incubation with both HDL (−1.44-fold, Benjamini–Hochberg-corrected P = 0.01, not shown
on Supplementary Data 1, which only includes genes significantly altered ≥1.5-fold) and
SUV (−1.54-fold, Benjamini–Hochberg-corrected P < 0.05, Supplementary Data 1) after 16
h. Moreover, VCAM-1 mRNA levels were also found to be significantly decreased by HDL
(−2.49-fold, Benjamini–Hochberg-corrected P < 0.01, Supplementary Data 1) and SUV
(−1.85-fold, Benjamini–Hochberg-corrected P < 0.05, Supplementary Data 1) treatments.
Real-time PCRs were used to further confirm that incubation of non-activated HCAEC with
native HDL resulted in significant loss of endothelial cell ICAM-1 (Fig. 2a) and VCAM-1
(Fig. 2b) mRNA levels. Lipid-free apoA-I, by contrast, failed to significantly reduce
adhesion molecule expression in non-activated HCAEC (Supplementary Data 1, Fig. 2a,b).
Granulocyte-macrophage colony-stimulating factor (GM-CSF), product of the CSF2 gene, is
a major pro-inflammatory cytokine that is secreted from endothelial cells, fibroblasts and
inflammatory cells35–37. Most interestingly, we found that native HDL treatment
significantly decreased CSF2 mRNA levels in HCAEC (Fig. 2c). In addition to CSF2, other
inflammatory genes were also found to be suppressed by HDL treatments, including
chemokine (C–C motif) ligand 20 (CCL20) and chemokine (C–X–C motif) ligand 1
(CXCL1) (Supplementary Data 1). CXCL1 is another endothelial cytokine involved in both
inflammation and angiogenesis38. Moreover, incubations with native HDL also decreased
the mRNA levels of PR domain zinc finger protein 1 (PRDM1 or BLIMP-1) in non-activated
endothelial cells (Fig. 2d). PRDM1 is a key transcriptional repressor of beta-interferon
expression and plays a pivotal role in inflammation, haematopoietic stem cell differentiation
and beta-lymphocyte maturation into antibody-producing cells39. Strikingly, we found that
ATP-binding cassette transporter G1 (ABCG1) mRNA levels were significantly decreased in
HCAEC treated with SUV (−2-fold, Benjamini–Hochberg-corrected P < 0.01), rHDL (−2.4-
fold, Benjamini–Hochberg-corrected P < 0.01) and native HDL (−1.7-fold, Benjamini–
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Hochberg-corrected P < 0.01) (Supplementary Data 1). Endothelial cell ATP-binding
cassette transporter A1 (ABCA1) mRNA levels were also significantly decreased by rHDL
(−1.95-fold, Benjamini–Hochberg-corrected P = 0.0001, Supplementary Data 1), SUV
(−1.4-fold, Benjamini–Hochberg-corrected P < 0.01) and native HDL (−1.4-fold,
Benjamini-Hochberg–Hochberg- P < 0.01) treatments (not shown on Supplementary Data 1,
which only includes genes significantly altered ≥1.5-fold). Results for HDL treatments were
confirmed by real-time PCR (Fig. 2e–f).
HDL alters endothelial cell miRNA levels
To determine whether HDL, SUV, lipid-free apoA-I or rHDL differentially alter miRNA
levels in endothelial cells, real-time PCR-based TaqMan miRNA arrays were used to profile
HCAEC miRNA levels before and after treatments. HDL, SUV, lipid-free apoA-I and rHDL
all distinctly altered endothelial cell miRNAs (Supplementary Fig. 2, Table 1). Significant
differential miRNA changes were observed in endothelial cells treated with SUV (1 down),
lipid-free apoA-I (18 in total; 15 down; 3 up), rHDL (5 in total; 1 down; 4 up) and native
HDL (3 in total; 1 down; 2 up) (unpaired t-test P < 0.05; ≥1.5-absolute fold; Table 1,
Supplementary Fig. 2A–D). Strikingly, only native human HDL treatments were found to
significantly increase intracellular mature miR-223 levels in HCAEC (16.5-fold, unpaired t-
test P < 0.001, Table 1). This was confirmed by real-time PCR in replicate studies (Fig. 3a).
PBS incubation was used as a control.
In HCAEC, SUV treatments were found to only alter one miRNA in either direction,
miR-296-3p (−1.75-fold). Although lipid-free apoA-I treatments were found to only
downregulate a single gene at the mRNA level (Fig. 1b), these treatments resulted in the
significant increase and decrease of 3 and 15 miRNAs, respectively, including miR-100
(−1.76-fold), miR-17* (miR-17-3p, −3.97-fold) and miR-548p (4.18-fold). rHDL treatments
were found to increase four miRNAs, including miR-496 (2.91-fold), and decrease 1
miRNA, miR-943 (−2.61-fold, Table 1). Although multiple miRNAs were significantly
altered in these incubations, we failed to identify miRNAs that changed in the same
direction (either upregulated or downregulated) in incubations of HCAEC with any two of
the following: HDL, rHDL, lipid-free apoA-I or SUV.
To determine whether there are possible shared miRNAs that just missed our statistical
cutoff of P values < 0.05 and fold changes > 1.5, we loosened the stringency for filtering.
First, we compared miRNAs that were statistically different for each condition (unpaired t-
test P < 0.1). After grouping miRNAs by directional trend (up and down), we generated
Venn diagrams to identify overlapping miRNA changes (Supplementary Fig. 3A,B). This
strategy failed to find any overlap with the downregulated miRNAs (Supplementary Fig.
3B); however, in the upregulated set, two miRNAs were found to be commonly regulated by
rHDL and SUV, one miRNA by apoA-I and SUV, one miRNA by HDL and rHDL, one
miRNA by apoA-I and rHDL and 1 miRNA by HDL and apoA-I. We also found one
miRNA to be upregulated by apoA-I, SUV and rHDL (Supplementary Fig. 3A). Secondly,
we filtered miRNAs that were found to be altered > 1.5-absolute fold change, independent
of P values and statistical comparisons. Although less stringent than our previous analyses,
this strategy identified numerous miRNA commonly up- or downregulated by HDL, rHDL,
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lipid-free apoA-I and SUV (Supplementary Fig. 4A,B). We found 86 miRNAs commonly
upregulated (> 1.5-fold) by at least two conditions (> 1.5-fold, Supplementary Fig. 4A), 15
of which were upregulated by all apoA-I containing particles (rHDL, lipid-free apoA-I and
native HDL). Moreover, we identified one miRNA, miR-548L, that was upregulated in all
four conditions. In the miRNAs that were found to be downregulated > −1.5-fold, we
identified 53 miRNAs commonly downregulated by at least two conditions (Supplementary
Fig. 4B). Moreover, we found six miRNAs that were downregulated by all apoA-I
containing particles (rHDL, lipid-free apoA-I and native HDL) (Supplementary Fig. 4B).
Mature miR-223 is transferred from HDL to endothelial cells
To determine whether the intracellular increase in miR-223 levels was due to induced
transcription and processing or exogenous uptake, we designed a series of in vitro studies to
assess HDL-mediated endothelial cell effects. To distinguish between these two
possibilities, miR-223 transcription and processing was assessed in HCAEC after HDL
treatments. Most importantly, no evidence was found to suggest that miR-223 is transcribed
in endothelial cells, as primary mir-223 (pri-mir-223) and precursor miR-223 (pre-miR-223)
transcripts were undetectable by realtime PCR (Fig. 3b). Furthermore, the observed increase
in intracellular miR-223 levels was apparent after 30 min of incubation with native HDL,
statistically significant at 1 h (Fig. 3c). These data suggest that the observed increases in
cellular miR-223 levels are likely due to HDL transfer of miR-223, and not a consequence
of increased transcription. This is consistent with the findings that mature miR-223 levels
increased in a concentration-dependent manner in the HCAEC incubated with increasing
HDL concentrations (Fig. 3d). To determine whether the absence of miR-223 transcription
was specific to HCAEC, basal levels of pri-mir-223 and mature miR-223 were also
quantified in human umbilical vascular endothelial cells (HUVEC) (Supplementary Fig.
5A). Similarly to HCAEC, there was no evidence of miR-223 transcription in HUVEC, as
pri-mir-223 transcripts were undetectable by real-time PCR. Mature miR-223 levels in
HUVEC were found to be significantly lower than in HCAEC (unpaired two-tailed
Student’s t-test P = 0.0002, Supplementary Fig. 5A). Furthermore, native HDL treatments
increased intracellular mature miR-223 levels by 16.1-fold in the HUVEC (Mann–Whitney
nonparametric test P < 0.05, Supplementary Fig. 5B). To further rule out the possibility of
HDL-induced miR-223 transcription in HCAEC, cells were incubated with native HDL and
Actinomycin D, a chemical inhibitor of transcription. HDL-induced miR-223 changes were
found to be transcription-independent, as HDL incubations in the presence or absence of
Actinomycin D both significantly increased miR-223 levels 4.2- and 4.8-fold, respectively
(Fig. 3e). These results further support the possibility that the increase in endothelial cell
miR-223 levels reflects the transfer from HDL, rather than increased miR-223 transcription.
To establish that this observation is unique to miR-223, we quantified miR-29a, a miRNA
present in HCAEC, and found that neither HDL, nor Actinomycin D and HDL treatments
resulted in an increase in intracellular miR-29a levels (Supplementary Fig. 6A). To
demonstrate that Actinomycin D was successful in inhibiting transcription in these
conditions, ICAM-1 and VCAM-1 mRNA levels were quantified in the presence or absence
of Actinomycin D with or without HDL (Supplementary Fig. 6B,C), and we found that these
mRNAs were highly sensitive to the loss of transcription in these cells. To demonstrate that
miR-223 is not likely processed in HCAEC, we used siRNAs to knockdown Dicer1, a key
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miRNA processing enzyme, and quantified miR-223 levels by real-time PCR. Dicer1
mRNA levels were found to be decreased ~65% in Dicer siRNA-treated cells; however, we
found no difference in cellular miR-223 levels between HCAEC with or without Dicer
knockdown (Fig. 3f).
HDL-associated miRNAs are likely protected from circulating RNases in blood through
their association with HDL lipids and proteins40. When the RNAse A-treated HDL were
incubated with HCAEC, the miR-223 content of the cells was significantly lower than what
was observed in the cells that were incubated with untreated HDL (Supplementary Fig. 7).
To determine miRNA changes in HDL before and after incubation with HCAEC, we used
TaqMan Low-Density miRNA Arrays to quantify these changes. HDL-miR-223 levels were
found to be significantly decreased after incubation with HCAEC (−13.64-fold, unpaired t-
test P < 0.05, n = 4, Fig. 3g). This was further confirmed by individual TaqMan assays (Fig.
3h). The lack of miR-223 transcription in HCAEC was further confirmed by mining
previously reported data sets from the ENCODE project41 and analysing the region
corresponding to the pri-mir-223 promoter. When compared with GM12878 (lymphoblast)
and K562 (myeloblastoid) human cell lines, in which the promoter region of miR-223 has
very strong signals for open chromatin (DHS) and active transcription (K4me3, K36me3 and
K27ac); at this time no evidence suggests that these signals are apparent in endothelial cells
(HUVECs) (Supplementary Fig. 8).
HDL-miR-223 represses ICAM-1 expression and function
miRNA target prediction software (TargetScan) was used to identify potential miR-223
target genes in endothelial cells. The results established that human ICAM-1 harbours one
broadly conserved putative miR-223 target site within its 3′ untranslated region (3′ UTR)
(Supplementary Fig. 9A). Based on these data, we hypothesized that the anti-inflammatory
capacity of HDL is conferred in part by its ability to transfer miR-223 to endothelial cells
where it represses ICAM-1 expression. To determine whether miR-223 directly targets
ICAM-1 mRNA at this predicted target site, HEK 293 cells were co-transfected with
ICAM-1–3′ UTR luciferase reporters and a miR-223 mimetic. Over-expression of miR-223
significantly reduced normalized (Firefly/Renilla) luciferase activity in HEK 293 (Mann–
Whitney nonparametric test P < 0.01, Fig. 4a). To determine whether the predicted miR-223
target site is functional, HEK 293 cells were also co-transfected with miR-223 and an
ICAM-1–3′ UTR reporter construct containing a three-base deletion in the middle of the
predicted miR-223 seed site (3′ UTR 814–816). The target site three-base deletion abolished
the capacity of miR-223 to inhibit ICAM-1–3′ UTR luciferase activity. To demonstrate that
HDL deliver functional miR-223 that directly targets and represses ICAM-1 gene
expression, HCAEC were electroporated with luciferase gene reporters containing the full-
length ICAM-1–3′ UTR. We found significant loss of normalized (Firefly/Renilla) luciferase
activity after HCAEC were incubated with native HDL (1 mg protein per ml) (Fig. 4b,
Mann–Whitney non-parametric test P < 0.01). Moreover, native HDL failed to reduce
luciferase activity in HCAEC that were electroporated with mutant reporters where the
putative miR-223 target site was disrupted with the three-base deletion. These findings
strongly suggest that HDL repression of ICAM-1 is mediated, at least in part by miR-223
directly targeting the 3′ UTR of ICAM-1 in HCAEC.
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To determine whether ICAM-1 mRNA and protein levels are reduced when cellular
miR-223 levels are increased, HCAEC were transiently transfected with miR-223 mimics,
and ICAM-1 mRNA levels were found to be significantly decreased (Fig. 4c). Likewise,
ICAM-1 protein levels were also found to be significantly decreased, as assessed by western
blotting (Supplementary Fig. 9B) and flow cytometry (Fig. 4d). Transfection of HCAEC
with miR-223 mimics also inhibited the ability of TNF-α to increase endothelial cell
ICAM-1 expression (Fig. 4e). To demonstrate that HDL repression of ICAM-1 is dependent
upon miR-223 transfer and activity, we quantified HDL repression of ICAM-1 protein
expression in HCAEC in which miR-223 activity was inhibited using a miR-223-specific
hairpin inhibitor. Strikingly, we found that HDL were no longer able to decrease endothelial
cell ICAM-1 expression in both non-activated and TNF-α-activated cells (Fig. 4f,
Supplementary Fig. 10). ICAM-1 siRNA was used as a control (Fig. 4c–f).
As previously reported42, HDL treatments were found to significantly inhibit neutrophil
binding to activated HCAEC (one-way ANOVA and the Tukey’s multiple comparisons
post-test P < 0.05, Supplementary Fig. 11). To investigate the functional impact of
increasing mature miR-223 levels in HCAEC on neutrophil adhesion, binding assays were
carried out in TNF-α-activated HCAEC. We found that neutrophil adhesion was inhibited
equally effectively by HDL and miR-223 (one-way ANOVA and the Tukey’s multiple
comparisons post-test P < 0.05, Fig. 4g,h).
To additionally demonstrate that the transfer of miR-223 from HDL to HCAEC represses
inflammatory gene expression, HCAEC were treated with HDL from wild-type (WT) or
miR-223−/− mice. First, we compared miR-223 levels on mouse and human HDL isolated by
fast-protein liquid chromatography (FPLC) and found that mouse HDL has less miR-223
than human HDL (Fig. 5a), and we found the presence of miR-223 in HDL from WT mice,
but not miR-223−/− mice. Most interestingly, intracellular levels of miR-223 were
significantly less in HCAEC treated with HDL from miR-223−/− compared with WT HDL
(Fig. 5b). Strikingly, mRNA levels for two inflammatory genes, ICAM-1 and CSF2, were
found to be significantly increased in HCAEC treated with HDL from miR-223−/− mice
compared with WT mice (Fig. 5c). Similar to ICAM-1, CSF2 is also a predicted target of
miR-223 (Fig. 5d).
Discussion
Both HDL and miRNAs have been reported to regulate many key processes in endothelial
cells, including angiogenesis, senescence, differentiation and inflammation7,12,21,43–46. In
the present study, we found that HDL and their lipid and apolipoprotein constituents each
induce distinct gene changes and post-transcriptional regulation. Indeed, significant up- and
downregulation of specific endothelial miRNAs were observed after HDL, lipid-free apoA-
I, rHDL and SUV treatments. Here we demonstrate that miR-223 is transferred from native
HDL to endothelial cells, miR-223 is not transcribed in HCAEC and HDL do not induce
miR-223 transcription in endothelial cells, and miR-223 directly targets ICAM-1 in
HCAEC. These data support that HDL-miR-223 delivery confers, in part, HDL’s anti-
inflammatory capacity in endothelial cells.
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Native HDL is composed of many constituents, including bioactive lipids, apolipoproteins,
other proteins and miRNAs14,47,48. The extent to which these constituents contribute to
HDL-mediated gene regulation has not been systematically examined. One of the key
outcomes from this present study is that the individual constituents of HDL each alter the
expression of distinct sets of genes in endothelial cells. Many of these genes were
significantly altered in the same direction by lipids (SUV), rHDL and native HDL
treatments; and were thus classified as the ‘cholesterol efflux responsive gene set’, as the
common feature of each condition is the capacity to accept free cholesterol. The ‘cholesterol
efflux responsive gene set’ in HCAEC significantly modulate distinct pathways including
interferon signalling, LXR/ RXR activation and other inflammatory pathways (p38 MAPK
signalling, IL22 signalling, role of JAK1, JAK2 and TYK2 in interferon signalling, role of
JAK family kinases in IL-6-type cytokine signalling). It is noteworthy that HDL also inhibit
the expression of similar inflammatory pathways in macrophages by activating signalling
cascades through ABCA1 (refs 49,50), which was associated with membrane cholesterol
levels51,52. Indeed, multiple studies have found that HDL alter gene expression in cells that
they interact with, including macrophages49. The present study shows that HDL treatment in
endothelial cells resulted in the differential expression of multiple STAT3 target genes in
HCAEC, including nine genes recently identified as STAT3 target genes53. Most interesting,
ABCA1, the expression of which was significantly decreased in HCAEC incubated with
HDL in the present study, was also found to be a STAT3 target gene. HDL suppression of
ABCA1 was an unexpected finding and may be part of a novel feedback mechanism to
counter cellular cholesterol efflux; however, this will require further investigation. Likewise,
it is currently unknown whether this suppression is mediated through post-transcriptional
regulation, possibly through HDL-induced miRNA changes, or through inhibition of
transcriptional activation through any number of transcription factors, including liver ×
receptors (LXR) or Sp1 (refs 54–56).
Pathway analysis of gene expression indicated that the NF-κB signalling pathway in
HCAEC was significantly decreased by HDL. This is consistent with earlier studies in
which HDL inhibited TNF-α-induced adhesion molecule as well as cytokine and chemokine
expression in HCAEC and HUVEC7,57. Here we report that HDL markedly repressed
ICAM-1 and VCAM-1 expression in non-activated HCAEC. These results suggest that HDL
inhibit endothelial cell activation likely in part of a homoeostatic gene regulatory network.
The ability of HDL to inhibit inflammation in endothelial cells in the current study is not
limited to adhesion molecule expression, with many cytokines and chemokines, including
CCL20, CXCL1 and CSF2, being downregulated. In addition, PRDM1, a transcriptional
repressor and master regulator of antibody-producing cell maturation39 and interferon
signalling, were also found to be significantly inhibited by HDL treatments (Supplementary
Table 3). The physiological relevance of this control remains to be determined; however,
HDL control of transcription factor activities, namely PRDM1, will be of significant interest
in future studies.
In 2011, we reported that HDL transport specific miRNAs14 and miR-223 was found to be
the most significantly upregulated miRNA in HDL from human subjects with familial
hypercholesterolaemia, an inheritable disorder associated with markedly elevated plasma
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cholesterol levels, premature atherosclerosis and vascular inflammation14. miR-223 has
been reported to be a myeloid-specific miRNA and is highly expressed in neutrophils and
macrophages29; mature miR-223 is also present in other non-myeloid cell types, including
endothelial cells27,58. In our previous study, we reported that macrophages export miR-223
to HDL and that HDL delivers miR-223 to Huh7 hepatoma cells where it regulates gene
expression14. In this study, we report that HDL and their constituents each regulate distinct
miRNAs in endothelial cells. Nevertheless, HDL-induced miR-223 upregulation was unique
to native HDL. Therefore, we hypothesized that miR-223, one of the most abundant
miRNAs on native human and mouse HDL14, was transferred from HDL to endothelial cells
where it directly regulates target gene expression, including ICAM-1, which harbours a
strong predicted miR-223 target site that is broadly conserved amongst vertebrates. In this
study, we establish that mature miR-223 is abundant in endothelial cells (HCAEC and
HUVEC) where it is neither transcribed nor processed. This is explained by the transfer of
mature miR-223 from HDL to both HCAEC and HUVEC. The present report extends this
finding by establishing that HDL also transfers functional miR-223 to HCAEC where it
controls inflammatory gene expression. It is therefore likely that, in the context of
atherosclerosis and other inflammatory diseases, macrophages export miR-223 to HDL,
which in turn transfer miR-223 to endothelial cells as a feedback mechanism to antagonize
inflammation. The levels of extracellular miRNAs, specifically HDL-miR-223 levels, are
altered in disease states, including atherosclerosis and cardiovascular disease14,21. The
functional impact of HDL-associated miR-223 in the development and resolution of
atherosclerosis remains to be determined; however, results from this study support a role in
vascular inflammation.
Although little is currently understood concerning the functional relevance of extracellular
miRNAs in vivo, multiple studies in vitro clearly support that extracellular miRNAs are
likely transferred to recipient cells. We have previously reported that HDL-miRNAs are
taken up by HDL’s receptor, scavenger receptor BI (SR-BI), in Huh7 cells and in SR-BI-
overexpressing baby hamster kidney cells14. Endothelial cells also express SR-BI and we
predict that HDL-miRNA transfer to HCAEC is also mediated through SR-BI. However,
endothelial cells also express other scavenger receptors that have been found to take up
HDL-cholesteryl esters, including CD36 (refs 59,60). Currently, it is unclear whether other
HDL receptors take up HDL-miRNAs and whether other delivery mechanisms transfer
functional miRNAs to the cytoplasm of recipient cells. Likewise, it is unknown whether
HDL–miRNA intercellular communication is limited to only SR-BI-expressing cells. Future
studies will be required to demonstrate the functional role of SR-BI in HDL-miRNA
communication in vivo. Furthermore, it is unknown how HDL-transferred miRNAs escape
the plasma membrane and whether they are loaded onto endogenous RNA-induced silencing
complexes (RISC) and target mRNAs through canonical post-transcriptional mechanisms or
whether they utilize other cellular machinery and mechanisms to recognize and
translationally repress targeted mRNAs. Argonaute 2 (AGO2), the structure–function protein
of RISC, is predicted to prefer double-stranded duplexed miRNAs; however, HDL-miRNAs
are likely single-stranded and may be differentially loaded onto AGO2-RISC or other AGO
family members. If extracellular miRNAs regulate gene expression though distinct
mechanisms from endogenous miRNAs, cellular gene regulation may include bias and
Tabet et al. Page 10






















differential sensitivity to either class. Moreover, HDL-miRNA delivery through SR-BI may
bypass endosomal transport and lysosomes that may degrade extracellular RNAs, unlike
receptor-mediated endocytotic mechanisms. As such, differential modes of uptake likely are
associated with varied functional integrity of the extracellular miRNAs in recipient cells.
In summary, we present evidence that HDL and their individual constituents differentially
alter miRNA and gene (mRNA) profiles in endothelial cells. We also report that native HDL
transfer mature miR-223 to endothelial cells and miR-223 downregulates ICAM-1
expression. To our knowledge this is the first report of the presence of a mature miRNA
actively controlling gene expression in a cell in which it was not transcribed or processed.
These results not only confirm that miR-223 functions as a suppressor of inflammation in
activated and non-activated endothelial cells but also provides a novel insight into the
mechanism of the anti-inflammatory properties of HDL.
Methods
Isolation and characterization of native HDL and lipid-poor apoA-I
Blood was collected from five normal healthy donors (three females and two males, aged
25–35 years old) into EDTA-Na2 tubes and from autologously donated, pooled blood
samples from normal healthy donors (Healthscope Pathology, Australia). Native high-
density lipoproteins (HDL) were isolated by sequential ultracentrifugation in the 1.063 < d <
1.25 g ml−1 density range61, and the HDL isolated from the autologously donated blood
were delipidated using standard techniques62. Briefly, 10 ml methanol was added to 1–2 ml
of partly lyophilized HDL and the mixture was vortexed and left at room temperature for 1–
3 h or until the precipitate was clearly visible. Chloroform (10 ml) was added and the
solution was vortexed and left at room temperature for 10–30 min. Chilled ether (33 ml) was
then added and the mixture was chilled for 30 min. The mixture was then spun (1,500 r.p.m.,
4 °C) for 10 min and the supernatant was removed. Methanol (10 ml) was added to the pellet
and the mixture was briefly vortexed. Chilled ether (43 ml) was added to the mixture, which
was chilled for an extra 15 min. The mixture was spun (1,500 r.p.m., 4 °C) for 10 min and
the supernatant was removed. Methanol (10 ml) was again added to the pellet and the chilled
ether wash was performed twice. The resulting pellet was dried using nitrogen then
dissolved in 2 ml of 20 mM Tris (pH 8.2). Apolipoprotein (apo) A-I was isolated from the
resulting apoHDL by anion exchange chromatography63 on a Q Sepharose Fast Flow
column attached to an FPLC (Äkta) system (GE Healthcare, Chalfont St Giles, Bucks, UK).
As judged by electrophoresis on a homogeneous 20% SDS-Phast gel (GE Healthcare Bio-
Sciences) and Coomassie staining, the apoA-I was > 95% pure. Informed consent was
obtained from all subjects and the human research ethics committee (University of New
South Wales) approved these studies.
Plasma concentration of human HDL constituents
Blood was collected from five normal healthy donors (same as above) into EDTA-Na2 tubes
and native HDL were isolated using the Polyethylene Glycol 6000 (PEG-6000) method64.
Briefly, 1:1 v/v ratio of plasma and PEG were mixed. LDL/VLDL were allowed to
precipitate for 20 min on ice. The mix was centrifuged (15,000 r.p.m., 20 min) to pellet the
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LDL/VLDL fraction. The supernatant (HDL fraction) was carefully removed using a pipette.
The plasma concentration of the human HDL constituents, including apolipoprotein A-I
(apoA-I), apolipoprotein A-II (apoA-II), total cholesterol (TC), unesterified cholesterol
(UC); cholesterol esters (CE = TC-UC) and triglyceride (TG) were determined
enzymatically on a Beckman Coulter AU480 Auto-Analyser (Beckman Coulter, Inc.; CA,
USA).
Preparation and characterization of discoidal reconstituted HDL (rHDL)
rHDL containing apoA-I and 1-palmitoyl-2-linoleoyl phosphatidylcholine (PLPC; Avanti
Polar Lipids, Alabaster, AL) (initial PLPC:apoA-I molar ratio 100:1, final PLPC:apoA-I
molar ratio 80:1) were prepared by the cholate dialysis method65. Briefly, 53.06 µl of PLPC
(100 mg ml−1) was dried as a thin layer in a glass tube using nitrogen. Sodium cholate
(100.47 µl; 30 mg ml−1) was added and the tubes were briefly mixed. TBS was added to
give a final volume of 500 µl. The mix was vortexed every 15 min and allowed to stand on
ice until the mixture was optically clear. ApoA-I (2 mg) was added and the mixture was
allowed to stand on ice for an extra 2 h. The pooled mixtures were then dialysed (five times)
against 1 l TBS over 5 days. Particle sizes were determined by electrophoresis on 3–40%
non-denaturing polyacrylamide gradient gels and Coomassie staining with reference to
highmolecular weight standards of known diameter66.
Preparation of SUV
PLPC SUV were prepared as described67. Briefly, PLPC (39 µl of a 100 mg ml−1 solution in
ChCl3/MeOH (2/1, v/v)) was mixed with 20 µl of 1 mM butylated hydroxytoluene (BHT).
The mixture was dried under a rapid stream of nitrogen for 2 h at 40 °C. PBS was added to
the dried lipids and the mixture was sonicated for 5 min bursts in an ice bath until optically
clear. The solution was centrifuged for 10 min at 15,000 r.p.m. and the supernatant (SUV)
was collected. The phospholipid concentration was determined enzymatically on a Roche
Diagnostic/Hitachi 902 Auto-Analyser (Roche Diagnostics GmbH, Mannheim Germany)68.
Cell culture
HCAEC and HUVEC (Cell Applications, Inc. San Diego, CA), passages 3–6, were grown in
MesoEndo Growth Medium (Cell Applications, Inc.) containing 5% (v/v) serum and plated
24 h before use in 12 well plates at a density of 1 × 105 cells per well. HCAEC were
incubated at 37 °C for 16–24 h with SUV (final PLPC concentration 3 mmol l−1), lipid-free
apoA-I (final concentration 1 mg ml−1), rHDL (final apoA-I concentration 1 mg ml−1),
native HDL (final total protein concentration 1 mg ml−1) or PBS. To determine whether
HDL transport and deliver miR-223 to HCAEC, we examined HDL-associated miRNA
profiles before and after 16 h of incubation with HCAEC using real-time PCR-based
TaqMan miRNA arrays. Results were validated with individual TaqMan miRNA assays. To
determine whether HDL induce miR-223 transcription, HCAEC were treated with native
HDL particles in the presence of Actinomycin D (5 µg ml−1). HCAEC were also transfected
with miR-223 mimetics (100 nM). mRNA and protein levels of ICAM-1 were assessed
using real-time PCR, western blotting and flow cytometry.
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HCAEC were incubated at 37 °C for 16 h in a 5% (v/v) lipoprotein-depleted serum medium
with either native HDL from each of five donors (final protein concentration 1 mg ml−1),
rHDL (final apoA-I concentration 1 mg ml−1), lipid-free apoA-I (final concentration 1 mg
ml−1), SUV (final PLPC concentration 3 mmol l−1) or PBS. The cells were harvested and
total RNA was isolated using Qiazol miRNAeasy kits (Qiagen) and quantified by
spectrophotometry (Nanovue). Gene expression profiling was assessed using Affymetrix
GeneChip microarray assays according to the manufacturer’s protocol (Affymetrix). Briefly,
1 µg of total RNA was reverse transcribed (T-7 dT primers), amplified and biotinylated
(Affymetrix IVT Labelling Kit). Samples were hybridized to GeneChip Human Gene 1.0 ST
whole-genome arrays (28,869 genes) (Affymetrix), washed, stained (Affymetrix Fluidics
Station) and scanned (Affymetrix GeneChip Scanner). Relative quantitative values (RQV)
were used to determine mRNA levels; RQV = 2−dCt.
microRNA microarrays
HCAEC were incubated at 37 °C for 16 h in a 5% (v/v) lipoprotein-depleted serum medium
with either native HDL from each of five donors (final protein concentration 1 mg ml−1),
rHDL (final apoA-I concentration 1 mg ml−1), lipid-free apoA-I (final concentration 1 mg
ml−1), SUV (final PLPC concentration 3 mmol l−1) or PBS. Cells were harvested for real-
time PCR Taq-Man miRNA arrays (see below). Native HDL were extracted from the
medium by immunoprecipitation using 400 µl of 5.2 mg ml−1 goat anti-human apoA-I
microbeads (Academy Bio-Medical Company, Houston, TX, USA). HDL-miRNA profiles
before and after incubation with HCAEC were assessed by real-time PCR TaqMan miRNA
arrays (see below). Total RNA was isolated from HCAEC and native HDL pre- and post-
incubation with HCAEC by Qiazol miRNAeasy kits (Qiagen) according to the protocol
described by the manufacturer. Reverse transcription was performed using Human
MegaPlex RT Primer pools. cDNA was amplified using human MegaPlex PreAmp Primer
Pools and PreAmp Master mix. The amplified samples were loaded into Taqman microRNA
arrays (Part Number 4444913) Pool A (377 miRNAs) and pool B (373 miRNAs) and
analysed using the 7900 Real Time PCR System (Applied Biosystems). Ct values were
calculated by SDS 1.2 software (Applied Biosystems) and normalized to MammU6
(miRNA) housekeeping Ct values and expressed as 2−(Ct(microRNA) − Ct(U6)). For the miRNA
isolated from HDL pre- and post-incubation with HCAEC, results (Cts) were normalized to
the HDL total protein concentration determined by the BCA assay (Thermo Scientific,
USA).
Primary miRNA, precursor miRNA and mature miRNA individual TaqMan Assays
Total RNA was purified as outlined above and reversed transcribed using the TaqMan
microRNA reverse transcription kit (Applied Biosystems) according to the manufacturer’s
protocol. Subsequently, the reverse transcription product was used for detecting miRNA
expression by real-time PCR using individual TaqMan miRNA Assay Kits (Applied
Biosystems) for the specific miRNAs (Supplementary Table 8). Values were normalized to
U6 and expressed as 2−(Ct(microRNA) − Ct(U6)). For the quantification of pri-miRNA, total
RNA (900 ng) was reversed transcribed using the High capacity RNA-to-cDNA kit (Applied
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Biosystems) according to the instructions of the manufacturer. The reverse transcription
product (1.5 µl) was used for detecting pri-miRNA expression by qPCR using TaqMan Pri-
miRNA Assays (Applied Biosystems) for specific pri-miRNA (Supplementary Table 8).
Real-time PCR was performed with MyiQ single colour real-time PCR detection system,
using iQ SYBR Green Supermix (Bio-Rad) for relative mRNA quantification of precursor
miR-223. Values were normalized to human actin and expressed as
2−(Ct(Pri-microRNA] − Ct(Actin)) or normalizing Cts to PPIA. See Supplementary Table 8 for
details.
Transfections of HCAEC
HCAEC were plated at a density of 1 × 105 per well 24 h prior to transfection. Transient
transfections (50–100 nM, DharmaFECT 4, Dharmacon) were conducted for 48 h with hsa-
miR-223 miRIDIAN mimic, human Dicer (ON-TARGETplus SMARTpool Dharmacon),
miR-223 hairpin inhibitors (100 nM) or siRNA against human ICAM-1 (ON-TARGETplus
SMARTpool Dharmacon). siRNAs Dharmacon catalogue numbers are listed in
Supplementary Table 8.
Real-time PCR
Total RNA was isolated from HCAEC using miRNeasy mini kit (Qiagen) or Total RNA
Purification kits (Norgen). Reverse transcription was performed using 0.1 µg of RNA. Real-
time PCR was performed with MyiQ single-colour real-time PCR detection system, using iQ
SYBR Green Supermix (Bio-Rad) for relative mRNA quantification. Specific mRNAs were
also quantified by specific TaqMan probes (Life Technologies). PCR primers and TaqMan
Probes are listed in Supplementary Table 8.
Western blots
Cells were washed with ice cold PBS and lysed in 20 mM Tris buffer (pH 7.5), containing
0.5 mM EDTA-Na2, 0.5 mM EGTA-Na2 and proteases inhibitors. Cellular proteins were
resolved by SDS–PAGE and transferred electrophoretically to nitrocellulose membranes.
The membranes were incubated overnight using mouse anti-human monoclonal antibodies
directed against ICAM-1 (1:500) and β-actin (1:3,000) (Abcam, Cambridge, UK, all).
Respectively, 1:500 and 1:5,000 dilution anti-mouse IgG-HRP (Abcam) were used as
secondary antibodies. Immunoreactive proteins were detected by chemiluminescence and
analysed using Quantity One 1-D Analysis Software (Bio-Rad).
Flow cytometry
Cell surface ICAM-1 expression in HCAEC was determined by flow cytometry (Beckman
Coulter FC500, Fullerton, CA, USA) using FITCICAM-1 fluorescent antibodies. A FITC
IgG1 isotype non-specific antibody was used as negative control (BD Pharmingen). Briefly,
adherent cells were washed with cold PBS and then incubated for 30 min at 4 °C with 250 µl
of either ICAM-1 antibody or IgG1 isotype non-specific antibody (PBS + 10% human
serum). Cells were washed with cold PBS then detached using 2 mM EDTA in PBS. EDTA
was neutralized with PBS containing 10% human serum. Cells were transferred to eppendorf
tubes and washed (2–3 times) with PBS. Cell pellets were re-suspended in PBS containing
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2% human serum. Flow cytometry analyses were performed and forward scatter versus side-
scatter gates were set to include only viable cells. A number of events between 5,000 and
10,000 cells was analysed for each sample with a minimum of 65% viable cells. Changes in
mean fluorescence intensity were recorded.
3′ UTR luciferase reporter assays
HEK 293 and HCAEC were transfected for 48 h with 500 ng of the complete ICAM-1 3′
UTR (ICAM-1 1,331 bp, product ID: HmiT009184) hLuc-hRLuc luciferase reporter vector
(GebeCopoeia, Rockville, MD, USA) or 500 ng of the control construct (ENHO—Energy
Homoeostasis). HEK 293 cells were co-transfected with or without 100 nM of hsa-miR-223
miR-IDIAN mimic. HCAEC were incubated with or without HDL (1 mg total protein per
ml) 24 h before harvesting the cells. HEK 293 cells were transfected using DharmaFECT 4
transfection reagent (Dharmacon). HCAEC were transfected by electroporation using the
Neon Transfection kit and device (Life Technologies, NY, USA). The cells were washed
with PBS and lysed using Cell Culture Lysis Reagent (Promega, Madison, WI, USA).
Luciferase activities (luminescence ratio of Firefly/Renilla) were measured using the Luc-
Pair miR Luciferase Assay Kit (GebeCopoeia, Rockville, MD, USA).
Site-directed mutagenesis
Three bases (814–816) in the ICAM-1 3′ UTR plasmid construct were deleted using the
QuickChange II XL Site-Directed mutagenesis Kit (Agilent Technologies). Briefly, the
QuikChange II XL site-directed mutagenesis method was performed using PfuUltra high-
fidelity (HF) DNA polymerase for mutagenic primer-directed replication of both plasmid
strands. The oligonucleotide primers, each complementary to opposite strands of the vector,
were extended during temperature cycling by PfuUltra HF DNA polymerase, without
primer displacement. Forward 5′-ATTCCTCCCTTCCCCC CA
AAAACACCTTTGTTAGC-3′ and reverse 5′-GCTAACAAAGGTGTTTTT GGG
GGGAAGGGAGGAAT-3′ primers were used at a concentration of 125 ng µl−1. Extension
of the oligonucleotide primers generated a mutated plasmid containing staggered nicks.
Following temperature cycling, the product was treated with Dpn I. The Dpn I endonuclease
(target sequence: 5′-Gm6ATC-3′) is specific for methylated and hemi-methylated DNA and
was used to digest the parental DNA template and to select for DNA containing the deletion.
DNA isolated from almost all E. coli strains is dam-methylated and therefore susceptible to
Dpn I digestion. The nicked vector DNA incorporating the desired deletions was then
transformed into XL10-Gold ultracompetent cells. HEK 293 cells and HCAEC were
transfected with the mutated ICAM-1 3′ UTR hLuc-hRLuc luciferase reporter vector (500
ng) with or without 100 nM of hsa-miR-223 for HEK 293 cells and with or without HDL for
HCAEC (described above). The three-base deletion was confirmed by sequencing.
Neutrophil-endothelial cell attachment assay
HCAEC were grown in MesoEndo medium containing 5% (v/v) serum and plated on glass
coverslips in 12 well plates at a density of 1 × 105 cells per well. Cells were transiently
transfected for 48 h before use with 100 nM hsa-miR-223 miRIDIAN mimic or siRNA
control using the method described above. Native human HDL (final protein concentration 1
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mg ml−1) or PBS was added 16 h before use. After 48 h of transfection, cells were then
incubated at 37 °C for 5 h in the presence or absence of TNF-α (2 ng ml−1). Human
neutrophils were isolated using Polymorphprep (Axis-Shield, Olso, Norway) and incubated
for 15 min at 37 °C with 25 µM of the cell-tracing reagent, CellTrace CFCE cell
proliferation kit (Molecular Probes, Inc. Eugene, OR). Fluorescently labelled, isolated
human neutrophils (1 × 106, 100 µl) were added to HCAEC and incubated for 2 h. The cells
were gently washed with PBS (3 ×) and fixed on a slide using mounting media (Vectashield,
Vector Laboratories Inc., Burmingame, CA, US). Fluorescently labelled cells were
visualized on an inverted microscope and the number of adherent neutrophils was counted
using Image J software (NIH, US)42. Results are shown with values representing the mean ±
s.e.m.
RNAse A digestion
Density-gradient-ultracentrifuged purified native HDL was digested with RNAse A (400 µg
per mg total HDL protein) at 37 °C for 2 h followed by the addition of 2 × RNAse inhibitor
for 30 min at 37 °C to stop reaction. Treated and control (no RNAse A) HDL were
incubated with HCAEC for 24 h at a final concentration of 1 mg ml−1. Treated cells were
extensively washed and total RNA was isolated for downstream transcriptomics.
miR-223−/− mouse experiments
HDL was isolated from adult (2–6 months) miR-223−/− or C57BL/6 wild-type (WT) mouse
plasma using fast-protein liquid chromatography (FPLC). HCAEC were treated for 24 h
with pooled native HDL (final total protein concentration 1 mg ml−1) from 12 WT (mixed
gender, 6 males and 6 females) mice or 6 miR-223−/− mice (mixed gender, 5 males and 1
females). Mouse miR-223 (mmu-miR-223) levels in HDL and HCAEC (incubated with
HDL) were quantified by real-time PCR and normalized to U6 levels (HCAEC, RQV =
2−(Ct(miR-223)–Ct(U6)) or arbitrary Ct = 32 and total HDL protein (HDL). All mouse studies
were completed under active National Institutes of Health, National Heart, Lung and Blood
Institute Animal Care and Use Committee protocols, and all experiments complied with the
criteria outlined in the NIH ‘Guide for the Care and Use of Laboratory Animals’.
Informatics
miRNA target prediction studies were carried out using TargetScan 5.2.
(www.targetscan.org). High-level and low-level transcriptomics analyses were carried out
using GeneSpring GX12.0 (Agilent) (www.genomics.agilent.com). Pathway analyses were
carried out with Ingenuity Pathway Analyses. www.ingenuity.com.
Statistical analysis
Data are presented as mean ± s.e.m. When comparing two groups with a sample size ≥3, an
unpaired two-tailed Student’s t-test was used. Mann–Whitney nonparametric tests were used
to compare two independent groups with a sample size > 3. When data were paired and
samples size was > 3, Wilcoxon matched-pairs tests were used. One-way ANOVA and the
Newman–Keuls post-tests were used to compensate for multiple testing procedures. A value
of P < 0.05 was considered to be significant.
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Figure 1. HDL and its components distinctly alter gene expression in human endothelial cells
(a) HCAEC were incubated at 37 °C for 16 h with SUV (final PLPC concentration 3 mmol
l−1), (b) lipid-free apoA-I (final concentration 1 mg ml−1), (c) rHDL (final apoA-I
concentration 1 mg ml−1) or (d) native human HDL (final total protein concentration 1 mg
ml−1). Volcano plots of significant and differential HCAEC gene expression changes are
shown for five separate experiments (≥1.5-fold, Benjamini–Hochberg-corrected P < 0.05).
Red dots indicate genes with ≥1.5-fold change (Log2 fold change) and P < 0.05 (−Log10
corrected P-value). (e) Venn diagram of overlapping gene changes. Green circle (24 genes)
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and red circle (1 gene) identify common HCAEC genes that were respectively
downregulated or upregulated by SUV, rHDL and native HDL.
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Figure 2. HDL inhibits genes associated with inflammation and cholesterol efflux in endothelial
cells
ICAM-1 (a) and VCAM-1 (b) mRNA expression in HCAEC incubated with lipid-free
apoA-I, rHDL or native HDL as described in the legend to Fig. 1. CSF2 (c), PRMD1 (d),
ABCA1 (e) and ABCG1 (f) mRNA levels in HCAEC incubated with native HDL, as
quantified by real-time PCR. All data are presented as mean ± s.e.m. (N ≥ 4). Mann–
Whitney nonparametric test was used to compare two independent groups with a sample size
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> 3. When data were paired and samples size was > 3, Wilcoxon-matched-pairs tests were
used. *P < 0.05.
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Figure 3. HDL transfers miR-223 to human endothelial cells
(a) HCAEC were incubated with native HDL, lipid-free apolipoprotein A-I (apoA-I),
discoidal reconstituted HDL (rHDL) or SUV as described in the legend to Fig. 1.
Intracellular levels of mature miR-223 were quantified by real-time PCR using individual
TaqMan miRNA assays. RQV (normalized to U6) are reported as fold change (N = 5). (b)
Primary miR-223 (pri-mir-223, TaqMan Assays), precursor miR-223 (pre-miR-223, SYBR
green assays), and mature miR-223 (TaqMan assays) levels in HCAEC. RQV normalized to
peptidylprolyl isomerase A (PPIA) (N = 4). (c) Intracellular miR-223 levels in HCAEC after
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incubation with native HDL (final protein concentration 1 mg ml−1) for 30 min, 1, 4, 8 or 16
h, normalized to U6 and reported as fold change (N = 5–8). (d) Intracellular levels of
miR-223 levels in HCAEC incubated with increasing doses of HDL treatments for 24 h.
Results are normalized to U6 and reported as RQV (N = 3). (e) Intracellular miR-223 levels
in HCAEC pre-incubated with actinomycin D (5 µg ml−1, 8 h) followed by native HDL
incubation for 24 h, as quantified by real-time PCR, normalized to PPIA and reported as fold
change. (N = 3). (f) Intracellular levels of Dicer1 and miR-223 in HCAEC transfected with
100 nM siRNA against Dicer1, as quantified by real-time PCR. Results are normalized to
PPIA and reported as fold change. (N = 4). (g) miRNA profiling of HDL before (pre) and
after (post) incubation with HCAEC. Real-time PCR-based TaqMan Low-Density miRNA
arrays. Values are presented as a volcano plot of significant and differential HDL-associated
miRNA changes (≥1.5-fold, P < 0.05). (h) Validation of miR-223 levels in HDL pre/post
incubation with HCAEC, as quantified by individual TaqMan miRNA assays. (N = 4). All
data are presented as mean + s.e.m. Unpaired two-tailed Student’s t-test was used when
comparing two groups with a sample size ≥3. Mann–Whitney nonparametric test was used
to compare two independent groups with a sample size > 3. When data were paired and
samples size was > 3, Wilcoxon matched-pairs tests were used. To compare three or more
unmatched groups, one-way ANOVA and the Tukey’s multiple comparisons post-test was
used. *P < 0.05.
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Figure 4. miR-223 directly target ICAM-1 in HCAEC
(a) Normalized (Firefly/Renilla) luciferase activity in HEK 293 cells dual transfected for 48
h with miR-223 and luciferase gene reporters containing the full-length ICAM-1–3′ UTR, a
three-nucleotide (814–816) deletion in the predicted miR-223 target site or a control-3′
UTR. N = 3–9 (b) Normalized (Firefly/Renilla) luciferase activity in HCAEC transfected
with luciferase gene reporters containing the full-length ICAM-1–3′ UTR, a three-nucleotide
(814–816) deletion or control-3′ UTR for 24 h and incubated for a further 24 h with or
without native HDL. N = 3–18 (c) ICAM-1 mRNA levels in HCAEC transfected (48 h) with
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miR-223, control siRNA or targeting pool siRNA ICAM-1. N = 5–7 (d) ICAM-1 protein
levels 24, 48 and 72 after HCAEC were transfected with miR-223, ICAM-1 siRNA or
control siRNA, as quantified by flow cytometry. N = 4 (e) ICAM-1 protein levels in
HCAEC 72 h after miR-223, control siRNA or ICAM-1 siRNA transfection followed by ±
TNF-α (2 ng ml−1) for 5 h. N = 3–4 (f) ICAM-1 protein levels in HCAEC transfected with
miR-223 hairpin inhibitor, or ICAM-1 siRNA for 24 h followed by native HDL or PBS
incubations (16 h) and ± TNF-α for a further 5 h. N = 3–6 (a–f) All data are represented as
mean ± s.e.m. (g,h) Neutrophil-binding assays in activated HCAEC as described in the
Supplementary Information N = 4. The numbers of adherent neutrophils are presented with
values representing the mean + s.e.m. Unpaired two-tailed Student’s t-test was used when
comparing two groups with a sample size ≤3. Mann–Whitney nonparametric test was used
to compare two independent groups with a sample size > 3. When data were paired and
samples size was > 3, Wilcoxon matched-pairs tests were used. To compare three or more
unmatched groups, one-way ANOVA and Tukey’s multiple comparisons post-test were
used. *P < 0.05, **P < 0.01.
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Figure 5. HDL repression of inflammatory gene expression in HCAEC
(a) RQV of miR-223 levels in HDL isolated from human and mouse plasma by fast-protein
liquid chromatography (FPLC). Mouse plasma was pooled from six miR-223−/− mice and 12
WT mice for FPLC separation. (b,c) HCAEC were incubated with pooled native HDL (final
total protein concentration 1 mg ml−1) from WT or miR-223−/− mice for 24 h. (b) miR-223
levels were quantified by real-time PCR and normalized to U6 levels (RQV =
2−(miR-223 Ct—U6 Ct)). (N = 2–3). (c) ICAM-1 and CSF2 mRNA levels were quantified by
real-time PCR and normalized to peptidylprolyl isomerase A (PPIA) levels (RQV). (N = 2–
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3). (d) Predicted miR-223 target site within the 3′ untranslated region (3′ UTR) of the CSF2
(mRNA) gene.
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Table 1
Significant differential endothelial cell miRNA expression in response to HDL components.
Component miRNA Fold change P-value
Up
  apoA-I hsa-miR-1249 2.40 0.006
  apoA-I hsa-miR-374b* 2.39 0.012
  apoA-I hsa-miR-548P 4.18 0.038
  rHDL hsa-miR-1244 2.21 0.042
  rHDL hsa-miR-380 2.72 0.044
  rHDL hsa-miR-496 2.91 0.026
  rHDL hsa-miR-548d-3p 3.41 0.043
  Native HDL hsa-miR-223 16.51 5.09E − 04
  Native HDL hsa-miR-577 1.93 0.003
Down
  SUV hsa-miR-296-3p −1.76 0.035
  apoA-I hsa-miR-100 −1.75 0.041
  apoA-I hsa-miR-107 −2.03 0.036
  apoA-I hsa-miR-17* −3.97 0.046
  apoA-I hsa-miR-184 −3.17 0.003
  apoA-I hsa-miR-185 −2.01 0.016
  apoA-I hsa-miR-200b −2.31 0.033
  apoA-I hsa-miR-216a −3.07 0.012
  apoA-I hsa-miR-216b −2.03 0.018
  apoA-I hsa-miR-27a −2.01 0.044
  apoA-I hsa-miR-299-3p −2.02 0.016
  apoA-I hsa-miR-379 −1.74 0.033
  apoA-I hsa-miR-455-3p −1.76 0.041
  apoA-I hsa-miR-502-3p −2.01 0.019
  apoA-I hsa-miR-576-3p −1.53 0.031
  apoA-I hsa-miR-99b −1.73 0.034
  rHDL hsa-miR-943 −2.61 0.048
  Native HDL hsa-miR-339-5p −1.70 0.033
HCAEC were incubated at 37 °C for 16 h with SUV (final PLPC concentration 30 µmol ml−1), lipid-free apoA-I (final concentration 1 mg ml−1),
rHDL (final apoA-I concentration 1 mg ml−1) and native HDL (final total protein concentration 1 mg ml−1). miRNA levels were determined by
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